These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 24218420)

  • 1. Monitoring of unfractionated heparin in critically ill patients.
    Aarab R; van Es J; de Pont AC; Vroom MB; Middeldorp S
    Neth J Med; 2013 Nov; 71(9):466-71. PubMed ID: 24218420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
    Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
    Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accuracy of aPTT monitoring in critically ill patients treated with unfractionated heparin.
    van Roessel S; Middeldorp S; Cheung YW; Zwinderman AH; de Pont AC
    Neth J Med; 2014 Jul; 72(6):305-10. PubMed ID: 25319855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring of unfractionated heparin using activated partial thromboplastin time: an assessment of the current nomogram and analysis according to age.
    Kim JS; Lee HJ; Sung JD; Kim HJ; Lee SY; Kim JS
    Clin Appl Thromb Hemost; 2014 Oct; 20(7):723-8. PubMed ID: 23615295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin.
    Vandiver JW; Vondracek TG
    Pharmacotherapy; 2012 Jun; 32(6):546-58. PubMed ID: 22531940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher Maximum Doses and Infusion Rates Compared with Standard Unfractionated Heparin Therapy Are Associated with Adequate Anticoagulation without Increased Bleeding in Both Obese and Nonobese Patients with Cardiovascular Indications.
    Floroff CK; Palm NM; Steinberg DH; Powers ER; Wiggins BS
    Pharmacotherapy; 2017 Apr; 37(4):393-400. PubMed ID: 28107569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study.
    Samuel S; Allison TA; Sharaf S; Yau G; Ranjbar G; Mckaig N; Nguyen A; Escobar M; Choi HA
    J Clin Pharm Ther; 2016 Oct; 41(5):499-502. PubMed ID: 27381025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring.
    Vandiver JW; Vondracek TG
    Hosp Pract (1995); 2013 Apr; 41(2):16-24. PubMed ID: 23545756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of a Calculation-Free Weight-Based Unfractionated Heparin Nomogram With Anti-Xa Level Monitoring Compared With Activated Partial Thromboplastin Time.
    Kindelin NM; Anthes AM; Providence SM; Zhao X; Aspinall SL
    Ann Pharmacother; 2021 May; 55(5):575-583. PubMed ID: 32964730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin.
    Price EA; Jin J; Nguyen HM; Krishnan G; Bowen R; Zehnder JL
    Ann Pharmacother; 2013 Feb; 47(2):151-8. PubMed ID: 23386070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of 2 weight-based heparin dosing nomograms in neurology and vascular surgical patients.
    Marotti SB; Barras M; Kirkpatrick C
    Ther Drug Monit; 2015 Feb; 37(1):33-9. PubMed ID: 24831654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-factor Xa and activated partial thromboplastin time measurements for heparin monitoring in mechanical circulatory support.
    Adatya S; Uriel N; Yarmohammadi H; Holley CT; Feng A; Roy SS; Reding MT; John R; Eckman P; Zantek ND
    JACC Heart Fail; 2015 Apr; 3(4):314-22. PubMed ID: 25770404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Agreement between activated partial thromboplastin time and anti-Xa activity in critically ill patients receiving therapeutic unfractionated heparin.
    Ratano D; Alberio L; Delodder F; Faouzi M; Berger MM
    Thromb Res; 2019 Mar; 175():53-58. PubMed ID: 30708169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of the activated clotting time for monitoring heparin therapy in critically ill patients.
    De Waele JJ; Van Cauwenberghe S; Hoste E; Benoit D; Colardyn F
    Intensive Care Med; 2003 Feb; 29(2):325-8. PubMed ID: 12594595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of anti-Xa and activated partial thromboplastin time monitoring for heparin dosing in patients with cirrhosis.
    Fuentes A; Gordon-Burroughs S; Hall JB; Putney DR; Monsour HP
    Ther Drug Monit; 2015 Feb; 37(1):40-4. PubMed ID: 24901494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin Therapy: Issues and Recommendations.
    Marlar RA; Clement B; Gausman J
    Semin Thromb Hemost; 2017 Apr; 43(3):253-260. PubMed ID: 27272964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticoagulation monitoring part 2: Unfractionated heparin and low-molecular-weight heparin.
    Spinler SA; Wittkowsky AK; Nutescu EA; Smythe MA
    Ann Pharmacother; 2005; 39(7-8):1275-85. PubMed ID: 15956240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activated partial thromboplastin time and anti-xa measurements in heparin monitoring: biochemical basis for discordance.
    Takemoto CM; Streiff MB; Shermock KM; Kraus PS; Chen J; Jani J; Kickler T
    Am J Clin Pathol; 2013 Apr; 139(4):450-6. PubMed ID: 23525615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.
    Levine MN; Hirsh J; Gent M; Turpie AG; Cruickshank M; Weitz J; Anderson D; Johnson M
    Arch Intern Med; 1994 Jan; 154(1):49-56. PubMed ID: 8267489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin.
    Toulon P; Boutière B; Horellou MH; Trzeciak MC; Samama MM
    Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.